Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Rituximab + Utomilumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 12||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Utomilumab||PF-05082566|PF05082566||TNFRSF9 Antibody 14||Utomilumab (PF-05082566) is an activating monoclonal antibody that targets and antagonizes CD137 (4-1BB), potentially resulting in increased immune response against tumor cells (PMID: 27369047, PMID: 32144134).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01307267||Phase I||Rituximab + Utomilumab Utomilumab||A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab||Completed||USA||4|